BRISTOL-MYERS SQUIBB’s BETAPACE ANTI-ARRHYTHMIC BETA BLOCKER RECOMMENDED CONDITIONALLY FOR APPROVAL; ADMISSIBILITY OF INTERIM TRIAL DATA DEBATED

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".